{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:27:50Z","timestamp":1768292870139,"version":"3.49.0"},"reference-count":52,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2004,10,26]],"date-time":"2004-10-26T00:00:00Z","timestamp":1098748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    To determine the efficacy of risedronate in reducing vertebral fracture risk in women aged 80 and older with osteoporosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design:<\/jats:bold>\n                    Pooled analysis of data from three randomized, double\u2010blind, controlled, 3\u2010year\u2010fracture\u2010endpoint trials conducted from November 1993 to April 1998: Hip Intervention Program (HIP), Vertebral Efficacy with Risedronate Therapy\u2014Multinational (VERT\u2010MN), and VERT\u2010North America (NA).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting:<\/jats:bold>\n                    Office\u2010based practices, research centers, and osteoporosis clinics in Europe, North America, and Australia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Participants:<\/jats:bold>\n                    Osteoporotic (femoral neck bone mineral density T\u2010score &lt; \u22122.5 standard deviations or at least one prevalent vertebral fracture) women aged 80 and older.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Intervention:<\/jats:bold>\n                    Patients received placebo (n=688) or risedronate 5\u2003mg\/d (n=704) for up to 3 years. All patients received 1,000\u2003mg\/d calcium and, if baseline levels were low, up to 500 IU\/d vitamin D.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements:<\/jats:bold>\n                    Cumulative incidence of new vertebral fractures.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    After 1 year, the risk of new vertebral fractures in the risedronate group was 81% lower than with placebo (95% confidence interval=60\u201391%;\n                    <jats:italic>P&lt;<\/jats:italic>\n                    .001). The number of women who needed to be treated to prevent one new vertebral fracture after 1 year was 12. This early onset of efficacy was consistent across the clinical programs, and antifracture efficacy was confirmed over 3 years. Risedronate was well tolerated, with a safety profile comparable with that of placebo.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    These findings provide the first evidence that, even in the very old, reducing bone resorption rate remains an effective treatment strategy for osteoporosis. Because each therapeutic agent used for the treatment of osteoporosis may have unique characteristics, the observations made in this study should not be assumed to apply to other bisphosphonates.\n                  <\/jats:p>","DOI":"10.1111\/j.1532-5415.2004.52506.x","type":"journal-article","created":{"date-parts":[[2004,10,26]],"date-time":"2004-10-26T09:51:27Z","timestamp":1098784287000},"page":"1832-1839","source":"Crossref","is-referenced-by-count":144,"title":["Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old"],"prefix":"10.1111","volume":"52","author":[{"given":"Steven","family":"Boonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada","family":"El\u2010Hajj Fuleihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian P.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01623271"},{"key":"e_1_2_6_3_2","first-page":"1051","article-title":"The incidence of vertebral fractures in men and women","volume":"17","author":"Van der Klift M","year":"2002","journal-title":"The Rotterdam Study"},{"issue":"17","key":"e_1_2_6_4_2","first-page":"716","article-title":"Incidence of vertebral fracture in Europe","author":"European Prospective Osteoporosis Study (EPOS) Group.","year":"2002","journal-title":"Results from the European Prospective Osteoporosis Study (EPOS)"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(01)00614-7"},{"issue":"2","key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/8756-3282(92)90189-4","article-title":"Epidemiology of vertebral osteoporosis","volume":"13","author":"Kanis JA","year":"1992","journal-title":"Bone"},{"key":"e_1_2_6_7_2","first-page":"1010","article-title":"The prevalence of vertebral deformity in European men and women","volume":"11","author":"O'Neill TW","year":"1996","journal-title":"The European Vertebral Osteoporosis Study"},{"key":"e_1_2_6_8_2","first-page":"373","article-title":"for the Belgian Hip Fracture Study Group. Costs induced by hip fractures","volume":"11","author":"Autier P","year":"2000","journal-title":"A prospective controlled study in Belgium"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050138"},{"key":"e_1_2_6_10_2","first-page":"793","article-title":"The association of radiographically detected vertebral fractures with back pain and function","volume":"128","author":"Nevitt MC","year":"1998","journal-title":"A prospective study"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a036281"},{"key":"e_1_2_6_12_2","first-page":"546","article-title":"A prospective study of the effect of fracture on measured physical performance","volume":"48","author":"Greendale GA","year":"2000","journal-title":"Results from the MacArthur Study\u2014MAC"},{"issue":"3","key":"e_1_2_6_13_2","first-page":"185S","article-title":"The clinical impact of vertebral fractures","volume":"18","author":"Gold DT.","year":"1996","journal-title":"Quality of life in women with osteoporosis"},{"key":"e_1_2_6_14_2","first-page":"515","article-title":"Hospitalization with vertebral fracture among the aged","volume":"3","author":"Jacobsen SJ","year":"1992","journal-title":"A national population-based study, 1986\u201389"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980170039"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb02641.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.1996.00440200087011","article-title":"Vertebral fracture and other predictors of physical impairment and health care utilization","volume":"156","author":"Huang C","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.3.320"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-11-919"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/17453679808997788"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.5.821"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980170138"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070075"},{"key":"e_1_2_6_24_2","first-page":"1215","article-title":"for the Study of Osteoporotic Fractures Research Group. Vertebral fractures and mortality in older women","volume":"159","author":"Kado DM","year":"1999","journal-title":"A prospective study"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116756"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050067"},{"key":"e_1_2_6_27_2","first-page":"2237","article-title":"Aging bone and osteoporosis","volume":"163","author":"Ettinger MP.","year":"2003","journal-title":"Strategies for preventing fractures in the elderly"},{"key":"e_1_2_6_28_2","first-page":"1063","article-title":"Treatment of osteoporosis","volume":"82","author":"Freedman KB","year":"2000","journal-title":"Are physicians missing an opportunity?"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00457-5"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070078"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.6.378"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219010-00001"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212033272305"},{"key":"e_1_2_6_34_2","first-page":"257","article-title":"Combined calcium and vitamin D3 supplementation in elderly women","volume":"13","author":"Chapuy MC","year":"2002","journal-title":"Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk"},{"key":"e_1_2_6_35_2","first-page":"1344","article-title":"for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris ST","year":"1999","journal-title":"A randomized controlled trial"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050010"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440503"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650080915"},{"key":"e_1_2_6_39_2","first-page":"2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures","volume":"280","author":"Cummings S","year":"1998","journal-title":"Results from the Fracture Intervention Trial"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050093"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.9.1321"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650111218"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002230001146"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020400"},{"key":"e_1_2_6_46_2","first-page":"637","article-title":"for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene","volume":"282","author":"Ettinger B","year":"1999","journal-title":"Results from a 3-year randomized clinical trial"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01623005"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441904"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-70709-4_34"},{"key":"e_1_2_6_50_2","first-page":"985","article-title":"Lifetime fracture risk","volume":"41","author":"Melton LJ","year":"1988","journal-title":"An approach to hip fracture risk assessment based on bone mineral density and age"},{"key":"e_1_2_6_51_2","first-page":"704","article-title":"A new probable increasing cause of esophageal ulceration","volume":"92","author":"Colina RE","year":"1997","journal-title":"Alendronate Am J Gastroenterol"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351403"},{"key":"e_1_2_6_53_2","first-page":"488","article-title":"Alendronate use among 812 women","volume":"4","author":"Ettinger B","year":"1998","journal-title":"Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-5415.2004.52506.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-5415.2004.52506.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:33:55Z","timestamp":1762187635000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-5415.2004.52506.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,26]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1111\/j.1532-5415.2004.52506.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-5415.2004.52506.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,26]]}}}